{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for abametapir in Related Substance Name (approximate match)
Status:
US Previously Marketed
Source:
XEGLYZE by HATCHTECH
(2020)
Source URL:
First approved in 2020
Source:
XEGLYZE by HATCHTECH
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Hatchtech is developing abametapir, an organic heterocyclic small-molecule, for the treatment of pediculosis (head lice). Abametapir is an inhibitor of metalloproteinases critical for louse survival and egg development. Abametapir lotion, 0.74%, demonstrated significant ovicidal activity against head lice eggs with a single application.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03830736: Not Applicable Interventional Completed Postprandial Glucose Regulation
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03830736: Not Applicable Interventional Completed Postprandial Glucose Regulation
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03333824: Phase 1 Interventional Completed Solid Tumours
(2017)
Source URL:
Class:
PROTEIN
